Physician profile
Coty Campbell
NPI 1265579106
$11,339.07
in general payments reported to CMS, 2019-2025
26 companies · $3,588 in 2025
The $3,588 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,236 · 2022: $1,434 · 2023: $2,179 · 2024: $2,902 · 2025: $3,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,604 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,603.77 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,989.61 | 2021-2025 | |
| Janssen Biotech, INC. | $1,576.67 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $957.60 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $793.62 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $732.76 | 2021-2025 | Dupixent |
| Pfizer INC. | $675.69 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $495.97 | 2021-2025 | |
| Amgen INC. | $458.22 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $423.88 | 2021-2024 | Ilumya |
| Leo Pharma INC. | $402.35 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $393.20 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $387.92 | 2023-2025 | Zoryve |
| Genzyme Corporation | $370.27 | 2021-2025 | |
| Galderma Laboratories, L.P. | $351.96 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $315.02 | 2021-2025 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $304.84 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $245.70 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Organon LLC | $109.68 | 2025 | Vtama |
| Almirall LLC | $109.07 | 2022-2024 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.35 | 2022-2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $58.37 | 2021 | |
| Mayne Pharma Commercial LLC | $36.68 | 2021-2023 | |
| Dermira, INC. | $24.49 | 2021 | |
| Epi Health, LLC | $18.96 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.00 | 2024 | Nuzyra |
| Solta Medical, A Division of Bausch Health US, LLC | $13.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coty Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.